Meiqi Chang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Meiqi Chang has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Yu Chen
Materdicine Lab School of Life Sciences Shanghai University Shanghai China
19 shared publications Xinran Song
Guangzhou Key Laboratory of Medical Nanomaterials, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong‐Hong Kong Joint Laboratory for RNA Medicine, Medical Research Center, Sun Yat‐Sen Memorial Hospital Sun Yat‐Sen University Guangzhou China
7 shared publicationsYanqiu Duan
Science and Technology Innovation Center Shanghai Municipal Hospital of Traditional Chinese Medicine Shanghai University of Traditional Chinese Medicine Shanghai China
5 shared publicationsLili Liu
Materdicine Lab, School of Life Science Shanghai University Shanghai China
4 shared publications- Chenglong Zhu
Faculty of Anesthesiology, Changhai Hospital, Naval Medical University, Shanghai, China
2 shared publications - Hao Fu
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation Guangdong‐Hong Kong Joint Laboratory for RNA Medicine Guangzhou Key Laboratory of Medical Nanomaterials Medical Research Center Sun Yat‐sen Memorial Hospital Sun Yat‐sen University Guangzhou China
2 shared publications
Latest Publications
- Open Access
- 15 November 2026
- Published by Wiley in Advanced Science
Vanadium Oxide Nanoregulator Modulates cGAS‐STING Pathway‐Associated Immune Dysregulation in Sepsis
Sepsis is driven by cytosolic accumulation of mitochondrial DNA (mtDNA) and consequent overactivation of the cGAS‐STING axis, which serves as a nodal upstream trigger for innate immune dysregulation. However, interventions directly targeting this subcellular event remain largely unexplored. To fill this gap, we synthesized a library of vanadium oxide nanostructures with distinct morphologies and identified nanospheres (VO NSs) as the optimal candidate. These VO NSs act through a multimodal mechanism, scavenging reactive oxygen species, stabilizing mitochondrial membrane potential, and blocking permeability transition pore opening, to physically constrain mtDNA egress from mitochondria, thereby ablating STING‐dependent inflammatory signaling. In murine models of sepsis, administration of VO NSs confers marked survival advantage and robust protection against multi‐organ injury. Mechanistically, using STING‐knockout mice, we demonstrate that STING ablation fully recapitulates the prophylactic efficacy of VO NSs, establishing STING as the pivotal downstream mediator. Beyond acute protection, VO NSs preserve mitochondrial genomic integrity and have the potential to disrupt the self‐reinforcing cycle between oxidative stress and immune exhaustion. This work offers an initial demonstration of a subcellular‐targeted intervention strategy for sepsis regulation, while also highlighting the potential of a modular nanoplatform for broader application in mitochondrial dysfunction‐associated diseases.
- 15 November 2026
- Published by Wiley in Advanced Science
Open AccessVanadium Oxide Nanoregulator Modulates cGAS‐STING Pathway‐Associated Immune Dysregulation in Sepsis
Sepsis is driven by cytosolic accumulation of mitochondrial DNA (mtDNA) and consequent overactivation of the cGAS‐STING axis, which serves as a nodal upstream trigger for innate immune dysregulation. However, interventions directly targeting this subcellular event remain largely unexplored. To fill this gap, we synthesized a library of vanadium oxide nanostructures with distinct morphologies and identified nanospheres (VO NSs) as the optimal candidate. These VO NSs act through a multimodal mechanism, scavenging reactive oxygen species, stabilizing mitochondrial membrane potential, and blocking permeability transition pore opening, to physically constrain mtDNA egress from mitochondria, thereby ablating STING‐dependent inflammatory signaling. In murine models of sepsis, administration of VO NSs confers marked survival advantage and robust protection against multi‐organ injury. Mechanistically, using STING‐knockout mice, we demonstrate that STING ablation fully recapitulates the prophylactic efficacy of VO NSs, establishing STING as the pivotal downstream mediator. Beyond acute protection, VO NSs preserve mitochondrial genomic integrity and have the potential to disrupt the self‐reinforcing cycle between oxidative stress and immune exhaustion. This work offers an initial demonstration of a subcellular‐targeted intervention strategy for sepsis regulation, while also highlighting the potential of a modular nanoplatform for broader application in mitochondrial dysfunction‐associated diseases.
- 27 October 2026
- Published by Wiley in Advanced Materials
Nanocatalytic Inhibition of ROS‐Dependent GSDMD Palmitoylation Mitigates Sepsis Progression
Sepsis is a life‐threatening condition characterized by multiple organ dysfunction, high morbidity, and mortality. Gasdermin D (GSDMD)‐mediated pyroptosis constitutes a key pathogenic mechanism. Here, we discovered that GSDMD in peripheral blood mononuclear cells (PBMCs) from septic patients undergoes enhanced palmitoylation, driven by reactive oxygen species (ROS) and mediated by ZDHHC5/ZDHHC9 transferases. Targeting this new mechanism, we designed and screened vanadium oxide hydroxide nanosheets (VOOH NSs) as catalytic ROS scavengers and GSDMD palmitoylation inhibitor. Crucially, we investigated and optimized the exposure patterns of specific lattice planes to maximize their ROS‐eliminating capability. This intervention measure prevents GSDMD palmitoylation, inhibits both canonical and non‐canonical pyroptosis, alleviates inflammatory damage, and demonstrates potent therapeutic effects in two sepsis animal models. Validation in GSDMD‐knockout mice further confirms this palmitoylation pathway as the key therapeutic target. These results demonstrate that targeting ROS‐mediated GSDMD palmitoylation is a key therapeutic strategy for treating sepsis.
- 27 October 2026
- Published by Wiley in Advanced Materials
Nanocatalytic Inhibition of ROS‐Dependent GSDMD Palmitoylation Mitigates Sepsis Progression
Sepsis is a life‐threatening condition characterized by multiple organ dysfunction, high morbidity, and mortality. Gasdermin D (GSDMD)‐mediated pyroptosis constitutes a key pathogenic mechanism. Here, we discovered that GSDMD in peripheral blood mononuclear cells (PBMCs) from septic patients undergoes enhanced palmitoylation, driven by reactive oxygen species (ROS) and mediated by ZDHHC5/ZDHHC9 transferases. Targeting this new mechanism, we designed and screened vanadium oxide hydroxide nanosheets (VOOH NSs) as catalytic ROS scavengers and GSDMD palmitoylation inhibitor. Crucially, we investigated and optimized the exposure patterns of specific lattice planes to maximize their ROS‐eliminating capability. This intervention measure prevents GSDMD palmitoylation, inhibits both canonical and non‐canonical pyroptosis, alleviates inflammatory damage, and demonstrates potent therapeutic effects in two sepsis animal models. Validation in GSDMD‐knockout mice further confirms this palmitoylation pathway as the key therapeutic target. These results demonstrate that targeting ROS‐mediated GSDMD palmitoylation is a key therapeutic strategy for treating sepsis.
- Open Access
- 30 September 2026
- Published by Wiley in Advanced Science
Topological Quantum Biomaterials Enable Pyroptosis‐Senescence Coupling for Enhanced Colorectal Cancer Therapy
Inducing pyroptosis in tumor cells has emerged as a promising anticancer strategy. However, under sublethal oxidative stress, a considerable fraction of cancer cells evades pyroptosis and undergoes therapy‐induced senescence, which ultimately drives chronic inflammation and facilitates tumor relapse. Here, we report an ultrasound‐responsive sequential therapeutic strategy that orchestrates the pyroptosis‐senescence axis for improved colorectal cancer therapy. This sequential therapeutic strategy integrates two functional modules, including morphologically engineered Pd 3 Sn topological quantum biomaterials and senolytic agent piperlongumine. Upon ultrasound irradiation, the tailored Pd 3 Sn nanostructures generate reactive oxygen species, which subsequently trigger zDHHC5‐mediated S‐acylation of gasdermin D, thereby initiating pyroptosis in colorectal cancer cells. Benefiting from its facet dependent near Fermi level electronic states and favorable peroxide activation kinetics, Pd 3 Sn achieves substantially improved sonocatalytic performance, allowing for the controlled production of radicals and the accurate triggering of the pyroptosis cascade. Intriguingly, the senescence‐associated secretory phenotype factors released from pyroptotic cells drive the surviving cancer cells into a senescent state. These senescent cells are then selectively eliminated by piperlongumine, effectively abrogating their senescence‐associated pro‐tumorigenic effects. In subcutaneous and liver metastasis models, this nanoplatform significantly suppresses tumor progression, achieving an 83.4% tumor volume inhibition rate and minimal liver metastatic burden. This work opens the application of quantum biomaterials in biomedicine and establishes a new therapeutic paradigm for disease treatment.
- 30 September 2026
- Published by Wiley in Advanced Science
Open AccessTopological Quantum Biomaterials Enable Pyroptosis‐Senescence Coupling for Enhanced Colorectal Cancer Therapy
Inducing pyroptosis in tumor cells has emerged as a promising anticancer strategy. However, under sublethal oxidative stress, a considerable fraction of cancer cells evades pyroptosis and undergoes therapy‐induced senescence, which ultimately drives chronic inflammation and facilitates tumor relapse. Here, we report an ultrasound‐responsive sequential therapeutic strategy that orchestrates the pyroptosis‐senescence axis for improved colorectal cancer therapy. This sequential therapeutic strategy integrates two functional modules, including morphologically engineered Pd 3 Sn topological quantum biomaterials and senolytic agent piperlongumine. Upon ultrasound irradiation, the tailored Pd 3 Sn nanostructures generate reactive oxygen species, which subsequently trigger zDHHC5‐mediated S‐acylation of gasdermin D, thereby initiating pyroptosis in colorectal cancer cells. Benefiting from its facet dependent near Fermi level electronic states and favorable peroxide activation kinetics, Pd 3 Sn achieves substantially improved sonocatalytic performance, allowing for the controlled production of radicals and the accurate triggering of the pyroptosis cascade. Intriguingly, the senescence‐associated secretory phenotype factors released from pyroptotic cells drive the surviving cancer cells into a senescent state. These senescent cells are then selectively eliminated by piperlongumine, effectively abrogating their senescence‐associated pro‐tumorigenic effects. In subcutaneous and liver metastasis models, this nanoplatform significantly suppresses tumor progression, achieving an 83.4% tumor volume inhibition rate and minimal liver metastatic burden. This work opens the application of quantum biomaterials in biomedicine and establishes a new therapeutic paradigm for disease treatment.
- Open Access
- 24 September 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (39) , e71729
A Synergistic Sonosensitive Pyroptosis Nanoactivator for Efficient Lung Adenocarcinoma Therapy
The critical challenge of apoptosis resistance severely constrains the efficacy of conventional cancer therapies. To address this issue, this study turns to pyroptosis, a lytic cell death pathway, and develops a novel therapeutic strategy by repurposing triptolide (TPL), a natural compound from traditional Chinese medicine (TCM), as a potent pyroptosis inducer. We rationally co‐load TPL with the sonosensitizer rose bengal (RB) into a customized covalent organic framework (COF) to construct a synergistic nanoplatform (CRT). The “old drug, new trick” paradigm is potentiated by a nanomaterial‐mediated synergistic mechanism: US‐triggered reactive oxygen species (ROS) generation from RB orchestrates a dual action, simultaneously inducing direct mitochondrial damage and initiating the controlled release of TPL. This dual action creates a feed‐forward loop that drives the progressive amplification of cytotoxic signals from both agents, culminating in the cooperative and robust activation of caspase‐3/GSDME‐mediated pyroptosis. Consequently, this CRT platform effectively circumvents apoptotic resistance, demonstrating tumor‐selective accumulation, potent antitumor efficacy in lung cancer models, and a highly favorable biosafety profile. This work establishes a precise and noninvasive nanomedicine paradigm, highlighting how advanced biomaterial design can unlock the synergistic potential of repurposed drugs for next‐generation cancer therapy.
- 24 September 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (39) , e71729
Open AccessA Synergistic Sonosensitive Pyroptosis Nanoactivator for Efficient Lung Adenocarcinoma Therapy
The critical challenge of apoptosis resistance severely constrains the efficacy of conventional cancer therapies. To address this issue, this study turns to pyroptosis, a lytic cell death pathway, and develops a novel therapeutic strategy by repurposing triptolide (TPL), a natural compound from traditional Chinese medicine (TCM), as a potent pyroptosis inducer. We rationally co‐load TPL with the sonosensitizer rose bengal (RB) into a customized covalent organic framework (COF) to construct a synergistic nanoplatform (CRT). The “old drug, new trick” paradigm is potentiated by a nanomaterial‐mediated synergistic mechanism: US‐triggered reactive oxygen species (ROS) generation from RB orchestrates a dual action, simultaneously inducing direct mitochondrial damage and initiating the controlled release of TPL. This dual action creates a feed‐forward loop that drives the progressive amplification of cytotoxic signals from both agents, culminating in the cooperative and robust activation of caspase‐3/GSDME‐mediated pyroptosis. Consequently, this CRT platform effectively circumvents apoptotic resistance, demonstrating tumor‐selective accumulation, potent antitumor efficacy in lung cancer models, and a highly favorable biosafety profile. This work establishes a precise and noninvasive nanomedicine paradigm, highlighting how advanced biomaterial design can unlock the synergistic potential of repurposed drugs for next‐generation cancer therapy.
Defect‐Regulated Hetero‐Trimetallic Nanocatalysts Augment Sonocatalytic Dynamic Therapy by Charge Transfer Facilitation and Ferroptosis Cascade Induction
Sonocatalytic dynamic therapy (SCDT) is an emerging non‐invasive anticancer strategy that employs ultrasound to activate sonocatalysts for the generation of reactive oxygen species (ROS). The therapeutic efficacy of this process is fundamentally governed by the intrinsic performance of the sonocatalyst. However, the artificial engineering of high‐performance ROS‐generating sonocatalysts faces significant challenges, including low catalytic efficiency, high toxicity, and off‐target accumulation. Herein, we construct the distinct two‐dimensional ultrathin hetero‐trimetallic nanocatalysts rich in oxygen vacancies for efficient SCDT against tumor. This study elucidates the critical role of multi‐metal coordination bonds and abundant defects in modulating intrinsic sonocatalytic activity. The derived trimetallic‐organic framework nanosheets, featuring uniformly dispersed iron, cobalt, and nickel hetero‐single atoms, effectively optimize the active sites, thereby providing robust sonocatalytic activity for efficient ROS generation. Furthermore, the defect‐driven sonocatalytic process mitigates the limitations of ligand‐to‐metal charge transfer, significantly enhancing the charge transfer efficiency. The consequent ROS burst acts as a redox signaling molecule that amplifies oxidative stress within the tumor microenvironment. Concurrently, ROS‐mediated intervention in the glutathione peroxidase 4 and long‐chain acyl‐CoA synthetase 4 pathways promotes the lipid peroxidation, activating the ferroptosis cascade and efficiently inhibiting tumor growth. These findings underscore the considerable prospects of defect‐rich sonocatalysts in versatile biomedical applications.
Defect‐Regulated Hetero‐Trimetallic Nanocatalysts Augment Sonocatalytic Dynamic Therapy by Charge Transfer Facilitation and Ferroptosis Cascade Induction
Sonocatalytic dynamic therapy (SCDT) is an emerging non‐invasive anticancer strategy that employs ultrasound to activate sonocatalysts for the generation of reactive oxygen species (ROS). The therapeutic efficacy of this process is fundamentally governed by the intrinsic performance of the sonocatalyst. However, the artificial engineering of high‐performance ROS‐generating sonocatalysts faces significant challenges, including low catalytic efficiency, high toxicity, and off‐target accumulation. Herein, we construct the distinct two‐dimensional ultrathin hetero‐trimetallic nanocatalysts rich in oxygen vacancies for efficient SCDT against tumor. This study elucidates the critical role of multi‐metal coordination bonds and abundant defects in modulating intrinsic sonocatalytic activity. The derived trimetallic‐organic framework nanosheets, featuring uniformly dispersed iron, cobalt, and nickel hetero‐single atoms, effectively optimize the active sites, thereby providing robust sonocatalytic activity for efficient ROS generation. Furthermore, the defect‐driven sonocatalytic process mitigates the limitations of ligand‐to‐metal charge transfer, significantly enhancing the charge transfer efficiency. The consequent ROS burst acts as a redox signaling molecule that amplifies oxidative stress within the tumor microenvironment. Concurrently, ROS‐mediated intervention in the glutathione peroxidase 4 and long‐chain acyl‐CoA synthetase 4 pathways promotes the lipid peroxidation, activating the ferroptosis cascade and efficiently inhibiting tumor growth. These findings underscore the considerable prospects of defect‐rich sonocatalysts in versatile biomedical applications.
- 6 March 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (10) , 8634-8647
Iridium Nanoantidotes Attenuate Jellyfish Toxin-Induced Hepatotoxicity by Inhibiting Gasdermin D Palmitoylation
Jellyfish envenomation poses a significant clinical challenge, with Nemopilema nomurai (N. nomurai) venom capable of inducing life-threatening hepatotoxicity through mechanisms that remain poorly understood. Here, we demonstrate that its tentacle extract (TE) simultaneously triggers a reactive oxygen species (ROS) burst, activates the canonical NLRP3/Caspase-1/Gasdermin D (GSDMD) pyroptosis pathway, and induces ZDHHC9-dependent GSDMD palmitoylation, collectively contributing to hepatic injury. To counteract this dual-pathway activation, we engineered ultrasmall iridium nanoantidotes (Ir NAs) with multienzyme mimetic activities, which effectively scavenge ROS, thereby suppressing both NLRP3 inflammasome activation and GSDMD palmitoylation while preserving mitochondrial function. These nanoantidotes significantly attenuated hepatocyte pyroptosis and histopathological damage, reduced mortality in vivo, and exhibited favorable biocompatibility with rapid clearance. Our work not only identifies GSDMD palmitoylation as a critical event in jellyfish venom-induced hepatotoxicity but also presents a translatable nanotherapeutic strategy for marine envenomation and related inflammatory disorders.
- 6 March 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (10) , 8634-8647
Iridium Nanoantidotes Attenuate Jellyfish Toxin-Induced Hepatotoxicity by Inhibiting Gasdermin D Palmitoylation
Jellyfish envenomation poses a significant clinical challenge, with Nemopilema nomurai (N. nomurai) venom capable of inducing life-threatening hepatotoxicity through mechanisms that remain poorly understood. Here, we demonstrate that its tentacle extract (TE) simultaneously triggers a reactive oxygen species (ROS) burst, activates the canonical NLRP3/Caspase-1/Gasdermin D (GSDMD) pyroptosis pathway, and induces ZDHHC9-dependent GSDMD palmitoylation, collectively contributing to hepatic injury. To counteract this dual-pathway activation, we engineered ultrasmall iridium nanoantidotes (Ir NAs) with multienzyme mimetic activities, which effectively scavenge ROS, thereby suppressing both NLRP3 inflammasome activation and GSDMD palmitoylation while preserving mitochondrial function. These nanoantidotes significantly attenuated hepatocyte pyroptosis and histopathological damage, reduced mortality in vivo, and exhibited favorable biocompatibility with rapid clearance. Our work not only identifies GSDMD palmitoylation as a critical event in jellyfish venom-induced hepatotoxicity but also presents a translatable nanotherapeutic strategy for marine envenomation and related inflammatory disorders.
- Open Access
- 1 January 2026
- Published by Innovation Press Co., Limited in The Innovation Materials
- Vol. 4 (2) , 100212-1-100212-2
Acoustically activatable liposomes: An innovative platform for targeted drug delivery and neuromodulation
- 1 January 2026
- Published by Innovation Press Co., Limited in The Innovation Materials
- Vol. 4 (2) , 100212-1-100212-2
Open AccessAcoustically activatable liposomes: An innovative platform for targeted drug delivery and neuromodulation
- 6 August 2025
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 13 (36) , 11381-11391
A calcium manganese-based pancatalytic nanozyme as a cell pyroptosis inhibitor for efficient inflammatory bowel disease treatment
A CaMn2O4 pancatalytic nanozyme scavenges ROS and inhibits GSDMD cleavage, and ultimately attenuates colitis by suppressing pyroptosis.
- 6 August 2025
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 13 (36) , 11381-11391
A calcium manganese-based pancatalytic nanozyme as a cell pyroptosis inhibitor for efficient inflammatory bowel disease treatment
A CaMn2O4 pancatalytic nanozyme scavenges ROS and inhibits GSDMD cleavage, and ultimately attenuates colitis by suppressing pyroptosis.
- Open Access
- 7 July 2025
- Published by Springer Nature in Nano-Micro Letters
- Vol. 17 (1) , 1-55
Advanced Nanomedicines for Treating Refractory Inflammation-Related Diseases
This review examines inflammation as a physiological defense mechanism against infectious agents, physical trauma, reactive oxygen species (ROS), and metabolic stress, which, under dysregulated conditions, may progress into chronic diseases. Nanomedicine, which integrates nanotechnology with medicine, suppresses inflammatory signaling pathways and overexpressed pro-inflammatory cytokines, such as ROS, to address inflammation-related pathologies. Current advances in nanomaterial design and synthesis strategies are systematically analyzed, with parallel discussions on toxicity mechanisms, influencing factors, and evaluation methods that are critical for clinical translation. Applications of functional nanomaterials are highlighted in the context of refractory inflammatory conditions, including wound healing, gastrointestinal disorders, and immune, neurological, or circulatory diseases, along with targeted delivery strategies. Persistent challenges in nanomedicine development, such as biocompatibility optimization, precise biodistribution control, and standardized toxicity assessment, are critically assessed. By bridging material innovation with therapeutic efficacy, this review establishes a framework for advancing nanomedicine to improve treatment outcomes while addressing translational barriers.
- 7 July 2025
- Published by Springer Nature in Nano-Micro Letters
- Vol. 17 (1) , 1-55
Open AccessAdvanced Nanomedicines for Treating Refractory Inflammation-Related Diseases
This review examines inflammation as a physiological defense mechanism against infectious agents, physical trauma, reactive oxygen species (ROS), and metabolic stress, which, under dysregulated conditions, may progress into chronic diseases. Nanomedicine, which integrates nanotechnology with medicine, suppresses inflammatory signaling pathways and overexpressed pro-inflammatory cytokines, such as ROS, to address inflammation-related pathologies. Current advances in nanomaterial design and synthesis strategies are systematically analyzed, with parallel discussions on toxicity mechanisms, influencing factors, and evaluation methods that are critical for clinical translation. Applications of functional nanomaterials are highlighted in the context of refractory inflammatory conditions, including wound healing, gastrointestinal disorders, and immune, neurological, or circulatory diseases, along with targeted delivery strategies. Persistent challenges in nanomedicine development, such as biocompatibility optimization, precise biodistribution control, and standardized toxicity assessment, are critically assessed. By bridging material innovation with therapeutic efficacy, this review establishes a framework for advancing nanomedicine to improve treatment outcomes while addressing translational barriers.